Mahwesh Saleem1,2, Nathan Herrmann1,3, Adam Dinoff1,2, Michelle M Mielke4, Paul I Oh5,6, Prathiba Shammi7, Xingshan Cao8, Swarajya Lakshmi Vattem Venkata9, Norman J Haughey9,10, Krista L Lanctôt1,2,3,6. 1. Neuropsychopharmacology Research Group, Sunnybrook Health Sciences Centre, Toronto, ON, Canada. 2. Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada. 3. Department of Psychiatry, University of Toronto, Toronto, ON, Canada. 4. Departments of Neurology and Health Sciences Research, Mayo Clinic, Rochester, MN, USA. 5. Division of Clinical Pharmacology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada. 6. Toronto Rehabilitation Institute, Toronto, ON, Canada. 7. Neuropsychology, Sunnybrook HealthSciences Centre, Toronto, ON, Canada. 8. Evaluative Clinical Sciences, Sunnybrook Health Sciences Centre, Toronto, ON, Canada. 9. Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 10. Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Abstract
BACKGROUND: Early subtle deficits in verbal memory, which may indicate early neural risk, are common in patients with coronary artery disease (CAD). While exercise can improve cognition, cognitive response to exercise is heterogeneous. Sphingolipids have been associated with the development and progression of CAD, and impairments in sphingolipid metabolism may play roles in neurodegeneration and in the neural adaptation response to exercise. OBJECTIVE: In this study, change in plasma concentrations of sphingolipids was assessed in relation to change in verbal memory performance and in other cognitive domains among CAD subjects undertaking a 6-month cardiac rehabilitation (CR) program. METHODS: Patients with CAD (n = 120, mean age = 64±6 y, 84% male, years of education = 16±3) underwent CR with neuropsychological assessments and blood collected at baseline, 3-, and 6-months. Z-scores based on age, gender, and education were combined for verbal memory, visuospatial memory, processing speed, executive function, and global cognition tasks to calculate cognitive domain Z-scores. Plasma sphingolipid concentrations were measured from fasting blood samples using high performance liquid chromatography coupled electrospray ionization tandem mass spectrometry (LC/MS/MS). Mixed models were used to identify sphingolipids significantly associated with performance in verbal memory and other cognitive domains, adjusting for potential confounders. RESULTS: A decrease in ceramide C18:0 concentration was significantly associated with improvement in verbal memory performance (b[SE] = -0.51 [0.25], p = 0.04), visuospatial memory (b[SE] = -0.44 [0.22], p = 0.05), processing speed (b[SE] = -0.89 [0.32], p = 0.007), and global cognition (b[SE] = -1.47 [0.59], p = 0.01) over 6 months of CR. CONCLUSIONS: Plasma ceramide C18:0 concentrations may be a sensitive marker of cognitive response to exercise in patients with CAD.
BACKGROUND: Early subtle deficits in verbal memory, which may indicate early neural risk, are common in patients with coronary artery disease (CAD). While exercise can improve cognition, cognitive response to exercise is heterogeneous. Sphingolipids have been associated with the development and progression of CAD, and impairments in sphingolipid metabolism may play roles in neurodegeneration and in the neural adaptation response to exercise. OBJECTIVE: In this study, change in plasma concentrations of sphingolipids was assessed in relation to change in verbal memory performance and in other cognitive domains among CAD subjects undertaking a 6-month cardiac rehabilitation (CR) program. METHODS:Patients with CAD (n = 120, mean age = 64±6 y, 84% male, years of education = 16±3) underwent CR with neuropsychological assessments and blood collected at baseline, 3-, and 6-months. Z-scores based on age, gender, and education were combined for verbal memory, visuospatial memory, processing speed, executive function, and global cognition tasks to calculate cognitive domain Z-scores. Plasma sphingolipid concentrations were measured from fasting blood samples using high performance liquid chromatography coupled electrospray ionization tandem mass spectrometry (LC/MS/MS). Mixed models were used to identify sphingolipids significantly associated with performance in verbal memory and other cognitive domains, adjusting for potential confounders. RESULTS: A decrease in ceramideC18:0 concentration was significantly associated with improvement in verbal memory performance (b[SE] = -0.51 [0.25], p = 0.04), visuospatial memory (b[SE] = -0.44 [0.22], p = 0.05), processing speed (b[SE] = -0.89 [0.32], p = 0.007), and global cognition (b[SE] = -1.47 [0.59], p = 0.01) over 6 months of CR. CONCLUSIONS: Plasma ceramideC18:0 concentrations may be a sensitive marker of cognitive response to exercise in patients with CAD.
Authors: Walter Swardfager; Nathan Herrmann; Susan Marzolini; Paul I Oh; Mahwesh Saleem; Prathiba Shammi; Alexander Kiss; Jaclyn Cappell; Krista L Lanctôt Journal: Psychosom Med Date: 2011-08-01 Impact factor: 4.312
Authors: Jonathan Y Xia; William L Holland; Christine M Kusminski; Kai Sun; Ankit X Sharma; Mackenzie J Pearson; Angelika J Sifuentes; Jeffrey G McDonald; Ruth Gordillo; Philipp E Scherer Journal: Cell Metab Date: 2015-07-16 Impact factor: 27.287
Authors: Michelle M Mielke; Veera Venkata Ratnam Bandaru; Norman J Haughey; Peter V Rabins; Constantine G Lyketsos; Michelle C Carlson Journal: Neurobiol Aging Date: 2008-05-05 Impact factor: 4.673
Authors: Jose A Suaya; Donald S Shepard; Sharon-Lise T Normand; Philip A Ades; Jeffrey Prottas; William B Stason Journal: Circulation Date: 2007-09-24 Impact factor: 29.690
Authors: Francesco Giallauria; Rosa Lucci; Mariantonietta D'Agostino; Alessandra Vitelli; Luigi Maresca; Maria Mancini; Mario Aurino; Domenico Del Forno; Pantaleo Giannuzzi; Carlo Vigorito Journal: J Cardiovasc Med (Hagerstown) Date: 2009-10 Impact factor: 2.160
Authors: Xuewei Wang; Hai Bui; Prashanthi Vemuri; Jonathan Graff-Radford; Clifford R Jack; Ronald C Petersen; Michelle M Mielke Journal: J Alzheimers Dis Date: 2021 Impact factor: 4.160
Authors: Dana Mohammad; Nathan Herrmann; Mahwesh Saleem; Richard H Swartz; Paul I Oh; Janelle Bradley; Parco Chan; Courtney Ellis; Krista L Lanctôt Journal: BMC Geriatr Date: 2019-06-11 Impact factor: 3.921
Authors: Mahwesh Saleem; Nathan Herrmann; Adam Dinoff; Susan Marzolini; Michelle M Mielke; Ana Andreazza; Paul I Oh; Swarajya Lakshmi Vattem Venkata; Norman J Haughey; Krista L Lanctôt Journal: J Gerontol A Biol Sci Med Sci Date: 2020-03-09 Impact factor: 6.591
Authors: Celina S Liu; Nathan Herrmann; Bing Xin Song; Joycelyn Ba; Damien Gallagher; Paul I Oh; Susan Marzolini; Tarek K Rajji; Jocelyn Charles; Purti Papneja; Mark J Rapoport; Ana C Andreazza; Danielle Vieira; Alex Kiss; Krista L Lanctôt Journal: BMC Geriatr Date: 2021-12-04 Impact factor: 3.921
Authors: Parco Chan; Mahwesh Saleem; Nathan Herrmann; Michelle M Mielke; Norman J Haughey; Paul I Oh; Alexander Kiss; Krista L Lanctôt Journal: J Alzheimers Dis Date: 2018 Impact factor: 4.160
Authors: Cameron Isaacs-Trepanier; Mahwesh Saleem; Nathan Herrmann; Walter Swardfager; Paul I Oh; Benjamin I Goldstein; Jane Mitchell; Kim S Sugamori; Krista L Lanctôt Journal: J Alzheimers Dis Date: 2020 Impact factor: 4.472